• Research type

    Research Study

  • Full title

    Interstitial Lung Disease DNA Study



  • Contact name

    Philip Molyneaux

  • Contact email

  • Sponsor organisation

    Imperial College London

  • Duration of Study in the UK

    5 years, 0 months, 0 days

  • Research summary

    Pulmonary fibrosis or Interstitial Lung Disease (ILD) encompasses a wide spectrum of progressive and irreversible disorders destruction of the lung. Clinically this causes cough and progressive breathing difficulty, which in the majority of cases result in death. Currently, diagnosis is challenging, with a third of patients either falling outside of the current disease categories or are termed unclassifiable.

    Recent studies have highlighted similarities in genetic predisposition across a range of ILDs. The pipeline from the genetic makeup of an individual to proteins that are constructed from these genes can be viewed as a disease ‘fingerprint’ and scientific discovery along this path can lead to new understanding of pathogenesis.

    We hope to identify specific markers in the blood of patients with a range of ILDs that will sidestep conventional classifications, speeding up the diagnostic pathway and avoid some of the more invasive diagnostic tests currently being used in clinical practice.

  • REC name

    London - City & East Research Ethics Committee

  • REC reference


  • Date of REC Opinion

    10 Nov 2022

  • REC opinion

    Further Information Favourable Opinion

Shape the future of the HRA website.